Stephen Hall
Impact in
- Rheumatology top 0.05%
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
- Spondyloarthritis Studies and Treatments
- Hematology top 0.2%
- Autoimmune and Inflammatory Disorders Research
Papers in
- Rheumatology 88
- Rheumatoid Arthritis Research and Therapies 63
- Spondyloarthritis Studies and Treatments 28
- Systemic Lupus Erythematosus Research 22
- Hematology 39
- Autoimmune and Inflammatory Disorders Research 38
- Co-authors
- Rachelle Buchbinder (12 shared papers)Roy Fleischmann (11 shared papers)Mark C. Genovese (14 shared papers)Patrick Durez (10 shared papers)Philip J. Mease (11 shared papers)Ronald Pedersen (3 shared papers)Andrew Koenig (2 shared papers)Michelle Petri (2 shared papers)
- Journals
- Annals of the Rheumatic Diseases (29 papers)Minerals Engineering (10 papers)Lara D. Veeken (7 papers)The Lancet (6 papers)The Journal of Rheumatology (5 papers)
- Partner nations
- AustraliaUnited StatesUnited Kingdom
In The Last Decade
Stephen Hall
139 papers receiving 8.7k citations
Stephen Hall's Hit Papers
Peers
Comparison fields: 5 of 165
- Rheumatology 6.2k
- Hematology 2.5k
- Immunology 3.1k
- Genetics 1.1k
- Radiology, Nuclear Medicine and Imaging 1.1k
Countries citing papers authored by Stephen Hall
This map shows the geographic impact of Stephen Hall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen Hall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen Hall more than expected).
Fields of papers citing papers by Stephen Hall
This network shows the impact of papers produced by Stephen Hall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen Hall. The network helps show where Stephen Hall may publish in the future.
Co-authors
The 25 scholars most cited alongside Stephen Hall, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 145 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Hit paper breakdown → | 2011 | 1401 |
| 2 | Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial Hit paper breakdown → | 2008 | 652 |
| 3 | Tofacitinib versus Methotrexate in Rheumatoid Arthritis Hit paper breakdown → | 2014 | 598 |
| 4 | Takayasu arteritis. A study of 32 North American patients. Hit paper breakdown → | 1985 | 449 |
| 5 | Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study Hit paper breakdown → | 2008 | 432 |
| 6 | Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis Hit paper breakdown → | 2017 | 421 |
| 7 | Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis Hit paper breakdown → | 2013 | 366 |
| 8 | Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor Hit paper breakdown → | 2014 | 341 |
| 9 | Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial Hit paper breakdown → | 2018 | 331 |
| 10 | 2013 | 267 | |
| 11 | 2008 | 246 | |
| 12 | 2010 | 237 | |
| 13 | 2013 | 198 | |
| 14 | 2008 | 150 | |
| 15 | A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. | 2004 | 144 |
| 16 | 2016 | 134 | |
| 17 | 2002 | 129 | |
| 18 | 2010 | 116 | |
| 19 | 2020 | 113 | |
| 20 | 2015 | 101 |
About Stephen Hall
Stephen Hall is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Surgery, having authored 145 papers that have together received 9.0k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (63 papers), Autoimmune and Inflammatory Disorders Research (38 papers), Spondyloarthritis Studies and Treatments (28 papers), Chronic Lymphocytic Leukemia Research (22 papers), Systemic Lupus Erythematosus Research (22 papers), Psoriasis: Treatment and Pathogenesis (20 papers), Minerals Flotation and Separation Techniques (10 papers) and Lymphoma Diagnosis and Treatment (8 papers). The work is most often cited by research in Rheumatology (6.2k citations), Hematology (2.5k citations), Immunology (3.1k citations), Genetics (1.1k citations) and Radiology, Nuclear Medicine and Imaging (1.1k citations). Stephen Hall has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Rachelle Buchbinder, Roy Fleischmann, Mark C. Genovese, Patrick Durez, Philip J. Mease, Ronald Pedersen, Andrew Koenig, Michelle Petri, C Tănăsescu and A Gallacher. Their work appears in journals such as Annals of the Rheumatic Diseases, Minerals Engineering, Lara D. Veeken, The Lancet and The Journal of Rheumatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.